Drug Approval | July 03, 2023
Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The company reported lifetime high EBIDTA of Rs. 250 crores
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
